In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.
Host:
Michael R. Charlton, MBBS
Professor of Medicine
Co-Director, Transplant Institute
The University of Chicago
Chicago, IL
Dr. Charlton has reported the following relevant financial relationships with ineligible companies of any amount during the past 24 months:
Consulting Fees: 89Bio, Akero, Alnylam, Amgen, AMRA, BMS, Boehringer Ingelheim, Enanta, Fractyl, Galecto, Intercept Pharmaceuticals, Madrigal Pharmaceuticals, Merck, NGM Biopharmaceuticals, Novartis, Novo Nordisk, Pfizer, Sagimet, Siemens, Terns, Theratechnologies, Thetis, Rivus
Faculty:
Naga Chalasani, MD, FACG
David W. Crabb Professor of Gastroenterology and Hepatology
Indiana University School of Medicine
Vice President for Academic Affairs
Indiana University Health
Indianapolis, IN
Dr. Chalasani has reported the following relevant financial relationships with ineligible companies of any amount during the past 24 months:
Consulting Fees: Akero, Altimmune, BioMed, GSK, Ipsen, Madrigal Pharmaceuticals, Merck, Pfizer, Zydus
Ownership Interest: Avant Santé, Heligenics
Research: Boehringer Ingelheim, Exact Sciences
Mary E. Rinella, MD
Professor of Medicine
Director, Metabolic and Fatty Liver Disease
University of Chicago Medicine
Chicago, IL
Dr. Rinella has reported the following relevant financial relationships with ineligible companies of any amount during the past 24 months:
Consulting Fees: Boehringer Ingelheim, CytoDyn, GSK, HistoIndex, Incyte, Intercept Pharmaceuticals, Madrigal Pharmaceuticals, Novo Nordisk, Sonic, Takeda
Reviewers/Content Planners/Authors:
- Cindy Davidson has nothing to disclose.
- Brian P. McDonough, MD, FAAFP, has nothing to disclose.
- Susan Smith, MN, PhD, has ownership interest in Hepion Pharmaceuticals.
- Rosanne Strauss, PharmD, has nothing to disclose.